Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This trial is a multicenter, open-label, phase II trial conducted at 23 centers in China.
High-risk HER2 positive patients receive pyrotinib 400mg/day for one year or half year for
extented adjuvant therapy.